Benign and Reactive Conditions of Lymph Node and Spleen (Atlas of Nontumor Pathology)

Product Description

One of the main reasons that this Fascicle was undertaken is that for some years there has been no single, up-to-date book containing extensive information on benign and reactive lymphoid conditions. Although malignant processes garner the majority of attention, it is the benign processes that have an underlying complexity that is often an illustration of the delicate interplay of many components of the active immune system. In diagnosing the pathologic specimen, a basic approach is: 1) to determine if the process is benign or malignant, 2) if malignant, to characterize the origin of the malignancy, and 3) to subclassify or identify the process. In some cases, the first part-the question of benign versus malignant-cannot be resolved by histomorphologic evaluation alone. The second part of the approach has become considerably easier with the advent of immunophenotypic analysis. The final issue, that of identification of the pathologic process, may be of greater or lesser importance, depending on the clinical situation. If an exact diagnosis can be made, it can have several benefits. In the case of neoplastic processes, it may indicate the type of treatment and the prognosis. In benign processes, there are other important benefits as well. Although some therapies may be instituted in benign conditions, often simply naming a thing can have great benefit to the patient. It is important to realize that even in the case of a purely reactive process, finding a name, a category, a classification, can provide real peace-of-mind to the patient. As American Journal of Clinical Pathology declares, "The hundreds of images are the greatest asset of this book.

Customers Who Bought This Item Also Bought

*If this is not the "Benign and Reactive Conditions of Lymph Node and Spleen (Atlas of Nontumor Pathology)" product you were looking for, you can check the other results by clicking this link.  Details were last updated on Nov 2, 2024 04:27 +08.